Clinical quality executive with 28 years of diverse, comprehensive medical and scientific experience across GXP in clinical drug development. 
 
Proven record of accomplishments in implementing successful Inspection Readiness (IR) programs and effective management of regulatory inspections, leading to positive outcomes in sponsor and clinical investigator site inspections conducted by the FDA, MHRA, EMA and PMDA.
 
Diligently applying a broad range of leadership skills and technical expertise in realizing key quality directives and clinical program support through fulfilling roles of increasing responsibility in multiple Pharma/CRO firms.